Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats.

J Bone Miner Metab 2016 Jan 12;34(1):33-40. Epub 2015 Mar 12.

Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka, 618-8585, Japan.

This study examined the effects of a novel cathepsin K inhibitor, ONO-KK1-300-01 (KK1-300), used concurrently with parathyroid hormone (PTH) in ovariectomized (OVX) rats. KK1-300 (3 mg/kg, twice daily), alendronate (1 mg/kg, once daily) or vehicle were orally administered to OVX rats for 56 days, starting the day after ovariectomy, followed by combination treatment with or without PTH (3 μg/kg, subcutaneously three times a week) for another 28 days. OVX control animals exhibited a significant increase in both bone resorption (urinary deoxypyridinoline; DPD) and formation markers (serum osteocalcin) as well as microstructural changes associated with decreased bone mineral density (BMD). Combination treatment with KK1-300 and PTH significantly decreased urinary DPD and increased serum osteocalcin, indicating a sustained beneficial effect compared to the effect of each mono-therapy. On the other hand, combination therapy with alendronate and PTH weakened the PTH-induced increase in osteocalcin. In proximal tibia, combination treatment with KK1-300 and PTH increased BMD to a level significantly higher than that achieved following single treatment with KK1-300 or PTH alone. On the other hand, combination treatment with alendronate and PTH failed to produce any significant additive effect on BMD following single treatment with alendronate or PTH alone. Microstructural analysis revealed that the PTH-induced increase in bone formation (MS/BS and BFR/BS) was fully maintained following combination treatment with KK1-300 and PTH, but not following combination treatment with alendronate and PTH. These findings indicate that KK1-300, unlike alendronate, has an additive effect on the preventive action of PTH on bone loss in OVX rats.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-014-0643-1DOI Listing
January 2016
15 Reads
2.460 Impact Factor

Publication Analysis

Top Keywords

combination treatment
24
kk1-300 pth
16
treatment kk1-300
16
alendronate pth
16
ovx rats
12
treatment alendronate
12
pth
11
combination therapy
8
pth-induced increase
8
single treatment
8
increase bone
8
bone mineral
8
combination
8
cathepsin inhibitor
8
treatment
8
mg/kg daily
8
serum osteocalcin
8
parathyroid hormone
8
hand combination
8
mineral density
8

References

(Supplied by CrossRef)

P Garnero et al.
J Musculoskelet Neuronal Interact 2004

DM Black et al.
N Engl J Med 2003

SK Amugongo et al.
Osteoporosis Int 2014

Y Nishi et al.
J Bone Miner Res 1999

M Gowen et al.
J Bone Miner Res 1999

MS McQueney et al.
Protein Expr Purif 1998

BD Gelb et al.
Science 1996

R Eastell et al.
J Bone Miner Res 2014

DS Williams et al.
Bone 2013

Y Ochi et al.
Bone 2011

Y Ochi et al.
J Bone Miner Res 2004

Similar Publications